Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Castle Biosciences' AdvanceAD-Tx™ Test Receives 2026 MedTech Breakthrough Award for Genomics Innovation

This marks the fifth MedTech Breakthrough Award that Castle has earned for its innovative testing solutions FRIENDSWOOD, Texas, May 12, 2026 /PRNewswire/ -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that its AdvanceAD-Tx test has been selected as the winner of the "Genomics Innovation Award" in the 10th annual MedTech Breakthrough Awards program, which recognizes companies driving meaningful progress and improving patient care across the global health and medical technology industry. AdvanceAD-Tx is Castle's clinically validated gene expression profile (GEP) test designed to guide systemic treatment decision making in patients 12 and older with moderate-to-severe atopic dermatitis (AD).

Castle Biosciences Reports First Quarter 2026 Results

Delivered Q1 2026 revenue of $83.7 million Q1 2026 total test reports for our core revenue drivers (DecisionDx ® -Melanoma, TissueCypher ® ) increased 36% over Q1 2025 Raising full-year 2026 revenue guidance to $345-355 million from $340-350 million Conference call and webcast today at 4:30 p.m. ET FRIENDSWOOD, Texas, May 6, 2026  /PRNewswire/ -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced its financial results for the first quarter ended March 31, 2026.

Castle Biosciences Supports Nationwide Patient Advocacy and Screening Initiatives to Celebrate Skin Cancer Awareness Month

Longstanding collaborations with AIM at Melanoma, the Melanoma Research Foundation, The Skin Cancer Foundation, IMPACT Melanoma and The Sun Bus continue to advance awareness and education throughout May FRIENDSWOOD, Texas, May 5, 2026 /PRNewswire/ -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced its participation in a series of initiatives throughout May to celebrate Skin Cancer Awareness Month, including advocacy walks, community skin cancer screenings and patient education programs nationwide. These efforts are part of the Company's longstanding collaborations with multiple patient-focused organizations and ongoing commitment to advancing early detection, patient education and advocacy.

New Data at DDW 2026 Show TissueCypher® Testing Improves Risk Stratification and Drives Risk-Aligned Management in Barrett's Esophagus

Clinical studies from Mayo Clinic researchers demonstrate the TissueCypher test provides improved risk stratification and influences risk-aligned surveillance decisions in clinical practice, with one study showing changes in surveillance intervals in more than half of patients compared with recommendations guided by traditional histopathology, supporting more personalized, risk-aligned patient management. FRIENDSWOOD, Texas, May 4, 2026 /PRNewswire/ -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that new data generated by researchers at Mayo Clinic will be presented at Digestive Disease Week® (DDW 2026), taking place May 2–5 in Chicago.